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Abstract
Purpose of Review To provide a highlight of the current state of cell therapy for the treatment of critical limb ischemia in patients
with diabetes.
Recent Findings The global incidence of diabetes is constantly growing with consequent challenges for healthcare systems
worldwide. In the UK only, NHS costs attributed to diabetic complications, such as peripheral vascular disease, amputation,
blindness, renal failure, and stroke, average £10 billion each year, with cost pressure being estimated to get worse. Although giant
leaps forward have been registered in the scope of early diagnosis and optimal glycaemic control, an effective treatment for
critical limb ischemia is still lacking. The present review aims to provide an update of the ongoing work in the field of
regenerative medicine. Recent advancements but also limitations imposed by diabetes on the potential of the approach are
addressed. In particular, the review focuses on the perturbation of non-coding RNA networks in progenitor cells and the
possibility of using emerging knowledge on molecular mechanisms to design refined protocols for personalized therapy.
Summary The field of cell therapy showed rapid progress but has limitations. Significant advances are foreseen in the upcoming
years thanks to a better understanding of molecular bottlenecks associated with the metabolic disorders.
Keywords Critical Limb Ischemia . Diabetes Mellitus . MicroRNAs . Microvesicles . Proangiogenic cells . Vascular Stem and
Progenitor cells
Introduction
Type 2 diabetes (T2D) and its complications have become one
of the biggest threats to global health and economy [1].
Approximately 9% of adults in the UK were affected by dia-
betes in 2015 and 90% of them were diagnosed with T2D [2].
Endothelial dysfunction (ED) is acknowledged as a central
player in diabetic vascular complications, including retinopa-
thy, cardiomyopathy, renal failure, and diabetic foot [3]. The
evolution of diabetes-related peripheral vascular disease
(PVD) has been described at the cellular and tissue level.
Insul in res is tance and glucose level instabi l i ty /
hyperglycaemia are key causative factors in the onset of mi-
crovascular ED and microangiopathy, which worsens the is-
chemic effects of concurrent atherosclerotic macroangiopathy.
This detrimental combination results in progressive deteriora-
tion of tissue perfusion ultimately leading to critical limb is-
chemia (CLI) [4, 5].
CLI is defined as a clinical syndrome of chronic ischemic
pain, skin ulcerations, and eventually gangrene, and it is associ-
ated with a highly increased mortality risk. Current treatments
encompass pharmacological therapy and revascularization.
However, a significant number of CLI patients are ineligible to
reperfusion treatments because of the anatomic location of the
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lesions, the extent of the disease, and comorbidities. Such “no
option CLI” (NO-CLI) patients often require limb amputation as
an extreme life-saving procedure [6, 7]. However, the prognosis
remains poor; diabetes-related amputations have a high risk of
mortality, with a 5-year survival rate of 40–48%.
In the last 20 years, regenerative medicine treatments have
been proposed to address the unmet clinical needs of CLI
patients. Chronologically, gene therapy using growth factors
(GFs) was first introduced with the objective of fuelling repar-
ative angiogenesis in affected muscles. The approach has
shown some encouraging results, but continues to bear impor-
tant limitations, which were mainly attributed to the poor gene
transfer yield and limited duration of the effect, as well the
inability of a single growth factor to resolve the pathogenic
complexity of underlying molecular mechanisms [8–10].
More recently, the attention has shifted on micro-RNAs
(miRNAs). Several short non-coding RNA (ncRNA) se-
quences reportedly contribute to the pathogenesis and pro-
gression of CLI through modulation of several downstream
genes [11–13]. Moreover, miRNAs form functional clusters,
which cooperate but also interfere with each other in different
pathophysiological conditions. Hence, great interest has been
focused on miRNA therapeutics and on miRNA regulating
drugs [14–16]. Other categories of ncRNAs, including long
ncRNA (lncRNAs) and circular RNAs (circRNA), are emerg-
ing as key players in diabetes cardiovascular complications
[17, 18]. Finally, cell therapy has also been employed as a
regenerative treatment, with a growing number of clinical tri-
als exploring the potential in ischemic disease and CLI [7].
The benefit of injecting cells in ischemic tissues is mainly
attributed to the regulated release of growth factors, cytokines,
and genetic material, either in soluble or vesicle-embedded
form. Therefore, cell therapy represents a more global method
to address the pathophysiological aspects of vascular disease.
This review highlights the current state of cell therapy for
the treatment of CLI. First, we provide some examples of
studies using different cell types; second, we indicate how
T2D can influence the cell phenotype and behaviour, poten-
tially limiting the benefits or causing undesired effects; and
third, we will discuss the contribution of ncRNAs in the pos-
itive and adverse responses to the cell-based therapies. Our
perspective is that, in the near future, the fields of cell therapy,
gene therapy, and ncRNA therapy may advantageously con-
verge into an all-inclusive approach capable of improving the
quality of life and outcome of patients suffering from ischemic
complications of diabetes.
Cell Therapy for Vascular Regeneration
in Critical Limb Ischemia
Recent meta-analyses conducted on a multitude of clinical
trials suggest that autologous stem cell-based therapies can
actually improve the clinical outcome of diabetes-related
CLI patients [19, 20]. However, some level of inconsistency
has emerged; highlighting the need for further studies to better
define all the critical aspects of the therapeutic protocol, in-
cluding the source of the optimal cell type, the identification
and screening for predictors of efficacy, as well as the admin-
istration modalities such as injection sites and treatment fre-
quency. Table 1 illustrates examples of candidate cell types,
classified according to the tissue source.
In the next sections, we summarize the latest results in the
quest for a suitable cell therapy approach for NO-CLI.
Clinically relevant developments in the field have been
assessed by conducting a PubMed search of articles published
in the last 5 years, extending then to essential prior publica-
tions that have led to current state of the art. In particular, we
have revised the available evidence on mesenchymal stromal
cells, mononuclear cells, and resident vascular progenitor
cells.
Mesenchymal Stromal Cells
Mesenchymal stromal cells (MSCs) represent the leading cell
type used in regenerative therapies for the treatment of auto-
immune, inflammatory, and vascular diseases. MSCs secrete a
wide variety of pro-inflammatory and anti-inflammatory cy-
tokines, GFs, and prostaglandins under resting and inflamma-
tory conditions [21, 22, 35, 36]. These molecules are associ-
ated with immunomodulation, anti-apoptosis, angiogenesis,
cell growth and differentiation, as well as anti-fibrosis and
chemo-attraction [22, 37]. MSCs are currently considered
among the most promising cell types as a regenerative option
to the surgical treatment of CLI, as they provide some peculiar
advantages [38]. Additionally, they reportedly express low
levels of mayor histocompatibility complex (MHC) class II
molecule, allowing for their use in allogenic treatments that
would overcome specific functional limitations typical of T2D
[39]. MSCs of different origins have been pursued as candi-
date cell types for cell therapy of NO-CLI patients [40•], with
ongoing clinical trials mainly focusing on bone marrow-
derived MSCs (BM-MSCs).
CHAMP (Clinical and Histologic Analysis of
Mesenchymal stromal cells in amPutations, trial number:
NCT02685098) is an open label, single centre, non-
randomized phase I clinical trial started in September 2017
and due to be completed by the year 2025. The study plans
to enrol 16 patients requiring semi-elective lower extremity
major amputation and aims to verify the safety and efficiency
of concentrated BM aspirate (cBMA) and BM-MSCs intra-
muscular injection to NO-CLI patients [38]. This study was
set up to better understand the mechanisms involved in a pre-
vious phase I study showing that intramuscular administration
of MSCs-containing cBMA resulted in a 1- and 5-year ampu-
tation-free survival (AFS) rate of 86 and 74% respectively, a
11    Page 2 of 13 Curr Diab Rep (2021) 21: 11
result comparable to that achieved through revascularization
[41]. Another endpoint of the trial is to determine the safety
and efficacy at 6 months after injection, but also to inquire the
short-term engraftment of BM-MSCs, their remodelling and
paracrine activities after injection.
SAIL (allogeneic mesenchymal stromal cells for angiogen-
esis and neovascularization in no-option ischemic limbs, trial
number: NCT03042572) is a randomized, double-blind,
placebo-controlled clinical trial begun in 2018 and expected
to end by July 2021. It will provide additional data on the
safety and potential efficacy of allogeneic BM-MScs treat-
ment for NO-CLI [42].
Mononuclear Cells
Following the isolation of CD34+ angiogenic mononuclear
cells (MNCs) in 1997, a large number of studies have been
dedicated to the evaluation of efficacy and safety as angiogen-
ic cell therapy for NO-CLI patients [43••]. In a pioneering
study, Tateyshi and colleagues demonstrated that intramuscu-
lar administration of BM-MNCs improved transcutaneous ox-
ygen pressure (TcPO2), rest pain, and walking distance after
4-week and 6-month-follow ups compared to peripheral
blood-derived MNCs (PB-MNCs), which were used a cellular
control [44]. Several other studies reported a beneficial effect
of autologous BM-MNCs and cBMA on AFS rate, amputa-
tion, pain, quality of life, Rutherford classification, and ankle
brachial index (ABI) [45–47]. The benefit was attributed to
the support of neovascularization within the ischemic tissues
[35, 48•], via direct engraftment, differentiation into appropri-
ate tissue cells, and paracrine interaction with and stimulation
of resident vascular cells [49]. A novel paracrine mechanism
has been recently described for BM-MNCs, involving down-
regulation of the endogenous nitric oxide synthase (NOS)-
inhibitor asymmetric dymetylalanine [50].
Both BM-MNCs and PB-MNCs are still under preclini-
cal and clinical investigation [51–54]. The derivation of
MNCs from PB is attractive considering the procedural risk
associated with BM extraction [55]. Nonetheless, different
clinical trials reported contradictory outcomes with regard
to the improvement of ABI, ulcer healing, pain-free walk-
ing time, and limb salvage following the infusion of MNCs
in CLI patients [22, 24, 25, 35, 37]. The reason for such
variability might reside in the heterogeneous nature of
MNCs. Therefore, experts in the field have moved to the
evaluation of better defined MNC sub-populations, such as
CD34+ and CD133+ MNCs. The latest meta-analysis con-
ducted on clinical trials involving CD34+ MNCs indicates
these cells can effectively reduce the rate of major ampu-
tation, while improving ulcer healing parameters [56].
Another concept emerging from meta-analysis is that the
response to CD34+ MNCs may be dose-dependent. In sup-
port to this hypothesis, treatment of NO-CLI with GCS-F-
mobilized- or enriched CD34+ MNCs displayed encourag-
ing results [51, 57, 58]. Regarding mechanisms, previous
studies on CD34+ MNCs showed that they can improve
limb reperfusion through extracellular vesicle (EV)-mediat-
ed delivery of angiogenic miRNAs [22, 48•, 59, 60•]. In a
diabetic mice model of CLI, the use of conditioned media
collected from human CD133+ subset of CD34+ MNCs
accelerated wound closure and reparative angiogenesis
through paracrine signalling [61•]. Accordingly, a small-
sized clinical study on the CD133+ subset of granulocytes
colony-stimulating factor (GCS-F)-mobilized CD34+ PB-
Table 1 Human stem and progenitor cell sources and types.
Table source adapted in modified version from Hmadcha et al [21], and
Soria-Juan et al [22]. AF, amniotic fluid; AF-MSCs, amniotic fluid-
derived mesenchymal stem cells; AT, adipose tissue; AT-MSCs, adipose
tissue-derived mesenchymal stem cells; BM, bone marrow; BM-MSCs,
bone marrow-derived mesenchymal stem cells; BM-MNCs, bone
marrow-derived mononuclear cells; EPCs, endothelial progenitor cells;
HSCs, haematopoietic stem cells; PB, peripheral blood; PB-MSCs,
peripheral blood-derived mesenchymal stem cells; PB-MNCs,
peripheral blood-derived mononuclear cells; PL, placenta; PL-MSCs,
placenta-derived mesenchymal stem cells; UC, umbilical cord; UC-
MSCs, umbilical cord-derived mesenchymal stem cells; WJ, Wharton’s
jelly; WJ-MSCs, Wharton’s jelly-derived mesenchymal stem cells
Sources Tissue Stem and progenitor cells
Adult tissues BM HSCs, EPCs, BM-MNCs [23, 24]
PB PB-MNCs [25]
BM stroma BM-MSCs [26]
PB stroma PB-MSC [27]
AT AT-MSCs [28]
Skeletal and cardiac muscle, skin,
cartilage, oral cavity, dental pulp, etc.
MSCs and pericytes [29, 30]
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MNCs also provided encouraging results (75% general im-
provement, 62.5% complete wound healing) [62].
Recent data on the application of specific MNCs subpop-
ulations to NO-CLI treatment are therefore promising. Future
studies will necessarily benefit from the deeper knowledge of
the molecular mechanisms specific to T2D-related CLI.
Resident Vascular Progenitor Cells
Damage and pauperization of vascular cells, namely endothe-
lial cells (ECs), vascular smooth muscle cells (VSMCs), and
pericytes, represent a hallmark of microangiopathy.
Therefore, supplying a boost of vascular progenitor cells to
the site of ischemic injury, as a method of therapeutic
vasculogenesis, could alleviate local quantitative and qualita-
tive deficits and promote tissue reperfusion and repair.
Pericytes represent a viable source for such an endeavour,
due to their key role in supporting a stable vascularization and
in acting as the interface between vasculogenesis and
myogenesis [63••]. Recent evidence indicates in fact that
pericytes not only play a role in vascular reparative processes,
but also in regeneration of myocytes together with satellite
cells [63••]. Preclinical evidence suggests that transplantation
of pericytes could exert positive effects in different patholo-
gies, including myopathies and ischemic disease [64••,
65–67]. The use of pericytes as a cell source for the treatment
of NO-CLI is only recently beginning to gather attention. Our
group has provided compelling preclinical evidence of effica-
cy and safety in murine models [29, 61, 68•, 69, 70].
Nonetheless, autologous pericytes may be affected by under-
pinning pathology, as observed in T2D. We reported that
pericytes from limb muscles of patients with diabetic vascu-
lopathy display elevated levels of oxidative stress causing a
dysfunctional phenotype [64••]. In T2D mice, treatment with
dimethyl-2-oxoglutarate (DM-2OG), a tricarboxylic acid cy-
cle metabolite with antioxidant properties, could restore
pericyte redox balance and mitochondrial function, while con-
currently allowing for enhanced pericyte-endothelial crosstalk
[71•]. These results suggest that metabolic therapy may help
to prevent or slow down vasculopathy in skeletal muscles of
people with diabetes. Alternatively, allogeneic approaches
could be considered. A study conducted in mice of induced
limb ischemia showed an improvement in blood flow and
collateral artery diameter recovery in animals treated with al-
logeneic pericytes [72].
Regarding other vascular cells, a recent small-size phase Ib
clinical trial evaluated the efficiency of a 1:1 formulation con-
taining ECs genetically modified to constitutively express
angiopoietin-1 (ANG1) and VSMCs transfected with a vascu-
lar endothelial growth factor (VEGF) retroviral vector for the
treatment of NO-CLI. Some improvements were observed.
One-year amputation-free survival rate was 72% (13/18) for
Rutherford 4 and 5 patients, whereas all 5 patients with
Rutherford 6 underwent amputation. Of the 12 with non-
healing ulcers, 6 had complete healing and 2 others had a
significant reduction (> 66%) in ulcer size. Outcomes did
not associate with dose stratification. No severe adverse
events were observed related to the therapy [73].
Another promising approach that is expected to reach the
clinical trial stage soon involves the application of human-
induced pluripotent stem cells- (hiPSCs) or SCs-derived EC
products [74–77]. Evidence of efficacy was provided by a
recent preclinical study that reported an accelerated reperfu-
sion and increased capillary density in CLI mice treated with a
clinical grade hSCs-derived EC product [78]. Interestingly,
such product was composed of a heterogeneous cell popula-
tion, enriched in CD144 and CD31-positive-differentiated
ECs, but also expressing mesenchymal and pericyte markers,
thus indicating both ECs and pericytes could participate in the
therapeutic effect. Altogether, these studies suggest that com-
binations of specialized vascular cells may be optimally suited
to regenerate the vasculature of NO-CLI patients.
Diabetes-Related Limitations
The harsh tissue environment created by the combination of
diabetes and ischemia can hamper the functionality of candi-
date cell products for autologous and, potentially, allogeneic
treatments (Fig. 1). The following sections summarize rele-
vant molecular targets to improve cell therapy outcomes in
patients with T2D.
Molecular Alterations in Ischemic Tissue and
Circulating and Bone Marrow Resident Progenitor
Cells
T2D is associated with increased levels of mitochondrial and
endoplasmic reticulum (ER) oxidative stress, resulting from
hyperglycaemia-induced activation of the electron transfer
chain (ETC) in the mitochondria [79]. Consequently, large
amounts of reactive oxygen species (ROS) are produced and
diffused to the ER through the mitochondria-associated mem-
branes (MAMs).
An impairment of the protein-folding machinery triggers
autophagy, an important pathway that allows cells to dispose
of the ROS-damaged macromolecules. However, autophagy
is inhibited by insulin through the activation of mammalian
target of rapamycin (mTOR), which results in unc-51 like
autophagy activating kinase 1 (ULK1) inactivation under in-
sulin resistance conditions [80]. In line with this, recent evi-
dence reports an inhibition of mitophagy (mitochondria-
specific autophagy) in PB-MNCs from patients with T2D
[81]. Moreover, tumour suppressor-programmed cell death-4
(PDCD4) overexpression was demonstrated in diabetic PB-
MNCs [82•]. These results mirror the recent observation that
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the inhibition of autophagy associates with an increased ex-
pression of PDCD4 in a human cancer cell line [83].
Importantly, hyperglycaemia-induced accumulation of ad-
vanced glycation end-products (AGEs) and ROS production
concurrently results in endothelial nitric oxide synthase
(eNOS) dimer uncoupling, which leads to the accumulation
of highly reactive nitrogen species [84–86]. This, in turn, af-
fects the mobilization and function of BM-derived progeni-
tors, which are thought to have pro-angiogenic and healing
potential. Selective inhibition of the PI3K/Akt signalling path-
way during insulin resistance can contribute to eNOS-reduced
expression and function, thereby expanding the effect of dia-
betes on NO equilibrium [87, 88]. Excess ROS production
accelerates telomere length shortening, or telomeres attrition,
a process that is exacerbated in T2D. Telomeres attrition is
significantly higher in ECs and PB-MNCs from patients with
T2D, and is associated with faster vascular ageing [89].
Patients with T2D exhibit decreased circulating CD34+
MNCs, a deficit that predicts the risk of complications and
death [90, 91, 92••, 93, 94]. Various mobilizing mechanisms
contributing to the liberation of BM-resident progenitor cells
in the circulation are profoundly altered in T2D, a defect
known as mobilopathy or myelokathexis, with negative con-
sequences for physiologic hematopoiesis, immune regulation,
and tissue regeneration, as reviewed in [95]. Nociceptive per-
ception is depressed in CLI patients favouring the formation
of foot ulcers. Interestingly, depression of nociceptive reflexes
can also contribute to mobilopathy in mice and patients with
complicated T2D, reducing the recruitment of reparative cells
that express the nociceptive receptors [96, 97].
In addition to causing an altered progenitor cell mobiliza-
tion, T2D was shown to drastically alter the cellular composi-
tion of BM in favour of adipose tissue accumulation; this
transformation can hinder the intrinsic regenerative potential
of resident mesenchymal and hematopoietic cells and compro-
mise their utility for therapeutic transplantation purposes [98].
Moreover, our group has discovered that the in vitro migratory
activity of CD34+ MNCs positively correlated with
Fig. 1 Damaging effect of diabetes on stem/progenitor cells in bone
marrow and peripheral circulation. BM bone marrow, MNCs
mononuclear cells, MSCs mesenchymal stromal cells, ECs endothelial
cells, PB peripheral blood. This figure was created using images from
Servier Medical Art Commons Attribution 3.0 Unported License. (http://
smart.servier.com). Servier Medical Art by Servier is licensed under a
Creative Commons Attribution 3.0 Unported License
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cardiovascular death, independently from other predictive fac-
tors, such as age, coronary artery disease, serum C-reactive
protein, and glomerular filtration rate [82•]. At a first glimpse,
these findings may appear counterintuitive, considering that
migration is instrumental to BM-derived cells to reach dam-
aged tissues, unless these cells have turned into deleterious
elements because of T2D. In line with this possibility, a pilot,
phase IIa, double-blind, randomized, placebo-controlled trial
(NCT02790957) conducted in patients with T2D with ische-
mic wounds showed that mobilization treatment with the
CXCR4 antagonist plerixafor had negative effects on wound
healing as compared to the placebo, leading to premature trial
termination after a pre-planned interim analysis [99].
Equilibrium in the paracrine- and GAP junction-supported
crosstalk between vascular mural cells is impaired in T2D-
related CLI. Evidence suggests that such damage includes
permanent as well as transient epigenetic modifications that
could hinder the efficacy of pericytes and ECs in autologous
cell therapy [72, 100, 101]. Interestingly, the pericyte-EC
crosstalk is also altered in BM, with depression of AKT-
dependent angiocrine signalling being a hallmark of local mi-
croangiopathy [102, 103]. Transfection with the adenoviral
vector carrying the coding sequence for constitutively active
AKT rescued functional defects and angiocrine signalling in
BM pericytes, suggesting this could be a molecular target to
restore the progenitor cell niche [102]. Likewise, targeting
inflammatory cytokines could improve BM function in T2D.
Pharmacological inhibition of MCP-1 signalling reduced adi-
posity in BM of T2D mice, restoring, at least in part, the
balance between adipogenesis and hematopoiesis [104].
Taken together, these observations indicate that T2D sig-
nificantly affects the functionality of virtually all the cell types
currently considered as viable candidates for CLI cell therapy.
Therefore, innovative techniques able to restore the function-
ality of the transplanted cells, as well as the development of
reliable allogeneic alternatives, could represent valuable
choices for future research.
MicroRNAs in Diabetes-Related Vascular Disease:
Implications for Cell Therapy
The prolonged modification of the cellular epigenetic profile
because of a metabolic insult is known as metabolic memory.
Epigenetic modifications could significantly limit the efficacy
of autologous cell therapy in CLI-T2D patients [105–108].
Importantly, miRNAs can affect the epigenetic mechanisms
by targeting key enzymes involved in establishing epigenetic
memory. For instance, T2D is associated with upregulation of
pro-inflammatory miRNAs (e.g., miR-125b, mir-146a-5p,
and miR-29a-3p) in aortic ECs, causing a chronic inflamma-
tory status that closely resembles the senescence-activated se-
cretory phenotype (SASP). Notably, this phenomenon is
reversible, with miRNA inhibition being able to reverse
NF-κB pathway activation in vascular cells [109]).
The miR-126 offers another relevant example of the
miRNAs ability to modulate metabolic memory at different
levels. Indeed, miR-126 can bind the 3′-UTR regions of,
among others, insulin receptor substrate-1 (IRS-1), phospha-
tidyl inositol 3-phosphate kinase receptor-2 (PI3KR-2),
sprouty related EVH1 domain-containing-1 (SPRED-1), and
disintegrin and metalloproteinase domain-containing protein-
9 (ADAM-9). This multiple targeting respectively results in
IR modulation, EC survival and proliferation, and modulation
of cell migration [110–113]. In T2D, miR-126 is reportedly
downregulated, possibly due to a compensatory response to
insulin resistance, thereby contributing to ED and vascular
disease [114]. In diabetic mice, restoration of miR-126 levels
reduced PVD development [14, 113].MNCs isolated from PB
of diabetic patients displayed a downregulation of miR-126,
resulting in reduced proliferation and increased apoptosis
through upregulation of its target Spred1; whereas, forced
miR-126 expression improved efferocytosis in human macro-
phages [111].
Overexpression of circulating miR-15a and miR-16-1,
which shares a common pre-pri-miRNA under the transcrip-
tional control of E2F-1, is predictive of restenosis and limb
amputation in T2D-CLI patients undergoing percutaneous an-
gioplasty [115••]. In line with a negative influence of these
microRNAs on cell therapy, transplantation of PB-MNCs
ex vivo-engineered with anti-miR-15a/16 improved post-
ischemic blood flow recovery and muscular arteriole density
in immunodeficient mice [115••].
In vitro studies unravelled the role of hypoxia in the mod-
ulation of miR-532-5p and miR-210 in pericytes and MNCs,
respectively [12, 116]. Induction of miR-532-5p by hypoxia
results in ANG1 downregulation and pericyte dysfunction.
Whereas, in MNCs, induction of miR-210 by hypoxia leads
to ephrin A3 downregulation eventually enhancing the MNC
proangiogenic potential. Notably, ex vivo transfection of
MNCs with miR-210 overexpressing vectors resulted in en-
hanced angiogenesis stimulation following transplantation in
a mouse model of limb ischemia [12].
MiRNAs were also identified as important regulators of
adipose tissue functions and may link inflammation and
insulin resistance, as reviewed in [117]. Interestingly,
some of these adipo-miRNAs are also expressed by vascu-
lar cells and implicated in T2D and ageing-associated
vasculopaties [118].
These observations collectively point to miRNAs as
pivotal players in the onset and progression of T2D
and CLI. Consequently, miRNAs represent viable targets
for the development of therapeutic strategies including
ex vivo expression level modification in candidate cell
products. Table 2 provides a list of deregulated miRNAs
in T2D- related ED/CLI.
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Long Noncoding RNAs in Diabetes-Related Vascular
Disease: Implications for Cell Therapy
LncRNAs represent a class of transcribed RNA molecules that
are longer than 200 nucleotides and yet do not encode proteins.
Several lncRNAs participate in the regulation of stem cell prop-
erties including their potential for self-renewal and differentia-
tion, which help in maintenance of normal cell and tissue ho-
meostasis. We have recently reported a T2D-dependent mech-
anism involving miR-21 downregulation CD34+ MNCs and
induction of its inhibitory target PDCD4, a tumor suppressor
protein involved in programmed cell death [82•]. We also
found that several lncRNAs that act as sponges for miR-21
were overexpressed in CD34+ MNCs and PB of patients with
T2D. We proposed that this altered paracrine signalling may
convey antiangiogenic and proapoptotic features from CD34+
cells to the endothelium [82•]. The study has important impli-
cations for cell therapy, calling for caution in using CD34+ cells
that carry a proapoptotic and antiangiogenic molecular signa-
ture, e.g., low miR-21/high PDCD4.
Several lncRNAs are gathering attention as theragnostic tools
in vascular complications of T2D as reviewed in [132]. An ex-
ample can be found in MALAT-1, which is one of the most
studied lncRNAs expressed in ECs, where it regulates
hyperglycaemia-induced inflammatory process [133].
Moreover, its knockdown was associated to an amelioration of
ED [134]. Interestingly, MALAT-1 is also upregulated in
CD34+ cells from patients with T2D, suggesting a general im-
plication in vascular dysfunction and cell-related repair processes
[82•]. Another lncRNA, MEG-3, was associated with a protec-
tive effect towards high glucose (HG)-treated HUVECs [135].
Recent evidence suggests a role for circRNAs in diabetes-
related epigenetic regulation. CircRNAs represent a large class
of stable RNAs produced by circularization of specific exons.
In vivo, they are generated by the spliceosome via backsplicing
and can modulate gene expression through sequestration of
RNA-binding proteins, transcriptional regulation, or sequestra-
tion of their target miRNAs [136–138]. cPWWP2A is a
circRNA overexpressed by retinal pericytes of streptozotocin-
induced diabetic mice. It can be delivered to ECs through EVs-
Table 2 MiRNAs differently
expressed in patients with T2D
affected by CLI or ED. EPCs,
endothelial progenitor cells;
HUVECs, human umbilical vein-
derived endothelial cells; miRNA,
microRNA; MNCs, mononuclear
cells; PB, peripheral blood
miRNAs affected by ED/CLI in T2D Up/downregulation Sample type
miR-15a Up PB-EPCs, serum [115••]
miR-16-1 Up PB-EPCs, serum [115••]
miR-130a Down EPCs [119]
miR-126 Down EPCs [111]
miR-126-3p Down Plasma [120]
miR-21 Down EPCs [82•]
miR-21-5p Up Plasma [120]
miR-200b-3p Up Plasma [121]
miR-2115-3p Up Plasma [121]
miR431-5p Up Plasma [121]
miR-486-5p Up Plasma [121]
miR-210-3p Up Plasma [121]
miR-1264 Up Plasma [121]
miR323b-5p Up Plasma [121]
miR-5579-3p Down Plasma [121]
miR-665 Down Plasma [121]
miR-4285 Down Plasma [121]
miR-500a-3p Down Plasma [121]
miR-4739 Up Whole blood [122]
miR-342-3p Up PB EPCs [123]
miR-29 Down Arteriole biopsies [124]
miR-149-5p Down HUVECs [125]
miR-4463 Up Femoral arteries, HUVECs [126]
miR-423 Down Plasma [127]
miR-199a-3p Down PB [128]
miR-93 Up Plasma [129]
miR-23c Up PB-MNC, biopsies [130]
miR-92a Up PB [131]
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mediated paracrine signalling, resulting in miR-579 sequestration
and consecutive overexpression of ANG1, occludin, and sirtuin
1, thereby providing a protective effect [139]. Likewise, HG
condition triggers another protective mechanism involving the
circRNA-0054633-mediated downregulation of miR-218, even-
tually contrasting ED [140]. On the other hand, overexpression of
circHIPK3 has a deleterious effect in diabetic retinopathy through
sponging of miR-30a-3p [141]. Likewise, circRNA-ZNF609 si-
lencing was shown to ameliorate ED in a diabetic mice model
[142]. Another study showed that culturing HUVECs under HG
conditions activates circ-0068087, a sponge circRNA responsible
for the upregulation of NF-κB-mediated inflammation through
the downregulation of its target miR-197 [143].
Recent sequencing studies have advanced the understanding
of diversity in non-coding RNAs due to T2D. In a high through-
put RNA-sequencing study, the comparison between blood
samples from three just-diagnosed patients with T2D and three
healthy patients unravelled a multitude of differentially
expressed miRNAs, lncRNAs, circRNAs as well as mRNAs
[144]. Furthermore, another RNA-sequencing study comparing
patients with diabetes with and without diabetic foot complica-
tions showed that 632 mRNAs and 33 circRNAswere different-
ly expressed in the sera of the two groups [145].
Taken together, these results provide a plethora of potential
molecular targets to improve the functionality of autologous
cell therapy in the treatment of NO-CLI.
Conclusions
The quest for an alternative treatment to surgical amputation for
NO-CLI patients relentlessly strives on, as reported in this short
review, accompanied by the steadily expanding account of the
molecular networks embedded in the pathological milieu.
Several studies reported here highlighted the importance of stem
and progenitor cells as well as ncRNAs in such context. The
constantly growing acknowledgement of the molecular connec-
tions between CLI and T2D suggests novel therapeutic ap-
proaches will rise soon. We can therefore conclude that future
trends in CLI cell therapy will keep on pursuing the refinement
of the ideal strategy to achieve tissue reperfusion, TcPO2 in-
crease, pain at rest reduction, as well as improvement of painless
walking distance, AFS rate, and mortality rate. Additionally,
miRNAs emerge as essential therapeutic and diagnostic targets
as they are broadly involved in the mechanisms of neovascular-
ization. The wide range of recently discovered angiogenic
miRNAs associated with every known aspect of CLI pathophys-
iology is likely to provide a solid base to boost the sprouting of
innovative strategies and refine current cell therapy techniques
soon. The definition of reliable predictors of responsiveness to a
given treatment should also enhance the efficacy of future cell
therapy trials [146]. Finally, evidence reported in meta-analyses
indicate that large, double-blind, placebo-controlled, randomized
trials with long-term follow-up are mandatory to firmly establish
cell therapy as an acceptable treatment of CLI.
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